NCT02098889View on ClinicalTrials.gov

Safety Study of Hyoscine N Butyl Bromide in Active Management of Labor

PHASE4CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Labor Fast
Interventions
DRUG

hyoscine-N-butyl bromide(HBB)

A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor

DRUG

Saline

placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor

Trial Locations (1)

34100

Sisli Etfal Research and Training hospital, Obstetrics and gynecology department, Istanbul

All Listed Sponsors
lead

Sisli Hamidiye Etfal Training and Research Hospital

OTHER

NCT02098889 - Safety Study of Hyoscine N Butyl Bromide in Active Management of Labor | Biotech Hunter | Biotech Hunter